Pregnancy Specific Beta-1 Glycoprotein in Women with Eclampsia, Kaduna State, Nigeria
Jim M. Banda1*, Geoffrey C. Onyemelukwe2, Bolanle O. P. Musa2, Oladapo S. Shittu3, Zulai A. Sarkin-Pawa3, Aliyu A. Babadoko4, Aisha I. Mamman4, Adamu G. Bakari5, Suraj Junaid6
1Pathology Department, Faculty of Medicine, Kaduna State University, Kaduna, Nigeria.
2Immunology Unit, Department of Medicine, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
3Department of Obstetrics and Gynaecology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
4Department of Haematology and Blood Transfusion, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
5Department of Medicine, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.
6Federal College of Veternary and Medical Laboratory, National Veterinary and Research Institute, Vom, Nigeria.
DOI: 10.4236/oji.2015.55021   PDF   HTML   XML   4,391 Downloads   5,045 Views  


This was a comparative cross-sectional study of eclamptic and normal healthy pregnant women conducted in kaduna State, Nigeria to determine Pregnancy Specific beta-1 Glycoprotein (PSG-1) levels in the peripheral blood of third trimester women with eclampsia (EC; n = 38), normal healthy pregnant and non pregnant women controls (PC; n = 25 and NPC; n = 25 respectively), age and parity matched, attending labour rooms/wards and Antenatal Clinics (ANC) of Ahmadu Bello University Teaching Hospital Shika, Zaria and four other Hospitals in Kaduna state, Nigeria. Participants with smear positive malaria, seropositive for human immunodeficiency virus (HIV) or any other known clinical infection were excluded from this study. Pregnancy specific beta-1 glycoprotein levels were estimated using Quantikine ELISA kits. Data obtained were analyzed using SPSS version 20.0 (Chicago, USA) and Graph pad Prism 6.0. Results were expressed as mean ± standard deviation while Kruskal Wallis test was used to determine the significant differences. A p-value of less than 0.05 was considered to be significant. The mean serum level of PSG-1 in EC was 2.53 ± 0.11 pg/ml, PC; 2.56 ± 0.03 pg/ml) and NPC; 0.62 ± 0.20 pg/ml. There was no significant difference between EC and PC (P > 0.05). Pregnant women (with and without EC) had significantly higher mean serum values compared to NPC p < 0.05. While pregnancy was associated with high levels of PSG-1, the study did not support the hypothesis of low PSG-1 level in EC. A longitudinal study to capture changes in PSG-I levels in the course of pregnancy as they manifest is recommended.

Share and Cite:

Banda, J. , Onyemelukwe, G. , Musa, B. , Shittu, O. , Sarkin-Pawa, Z. , Babadoko, A. , Mamman, A. , Bakari, A. and Junaid, S. (2015) Pregnancy Specific Beta-1 Glycoprotein in Women with Eclampsia, Kaduna State, Nigeria. Open Journal of Immunology, 5, 260-265. doi: 10.4236/oji.2015.55021.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Ghulmiyyah, L. and Sibai, B. (2012) Maternal Mortality from Preeclampsia and Eclampsia. Seminars in Perinatology, 36, 56-59.
[2] WHO (2011) Recommendations for Prevention and Treatment of Preeclampsia and Eclampsia. WHO Department of Maternal and Child Health, Geneva.
[3] Acquaah-Arhin, R. and Kwakwukume, E.Y. (2003) Trends in Eclampsia in Ghana at Korle-Bu Teaching Hospital, Accra, Ghana. Nigerian Journal of Clinical Practice, 6, 1-4
[4] Adamu, Y.M., Salihu, H.M., Sathiakumar, N. and Alexander, G.R. (2003) Maternal Mortality in Northern Nigeria: A Population-Based Study. European Journal of Obstetrics Gynecology and Reproductive Biology, 109, 153-159.
[5] Igberase, G. and Ebeigbe, P. (2006) Eclampsia: Ten-Years of Experience in a Rural Tertiary Hospital in the Niger Delta, Nigeria. Journal of Obstetrics and Gynaecology, 26, 414-417.
[6] WHO (2004) Coverage of Maternity Care: A Listing of Available Information. World Health Organization, Geneva.
[7] Shah, A.K. (2009) Preeclampsia/Eclampsia.
[8] Saito, S., Nakashima, A., Sakai M. and Sakai, Y. (2007) The Role of Immune System in Preeclampsia. Molecular Aspect of Medicine, 28, 192-209.
[9] Duley, L. (2009) The Global Impact of Preeclampsia and Eclampisa. Seminars in Perinatology, 33, 130-137.
[10] Zhou, G.Q., Baranov, V., Zimmermann, W., Grunert, F., Erhard, B., et al. (1997) Highly Specific Monoclonal Antibody Demonstrates That Pregnancy-Specific Glycoprotein (PSG) Is Limited to Syncytiotrophoblast in Human Early and Term Placenta. Placenta, 18, 491-501.
[11] Kammerer, R. and Zimmermann, W. (2010) Coevolution of Activating and Inhibitory Receptors within Mammalian Carcinoembryonic Antigen Families. BMC Biology, 8, 12.
[12] Harris, S.J., Anthony, F.W., Jones, D.B. and Masson, G.M. (1984) Pregnancy-Specific Beta 1-Glycoprotein: Effect on Lymphocyte Proliferation in Vitro. Journal of Reproductive Immunology, 6, 267-270.
[13] Ha, C.T., Waterhouse, R., Warren, J., Zimmermann, W. and Dveksler, G.S. (2005) N-Glycosylation Is Required for Binding of Murine Pregnancy-Specific Glycoproteins 17 and 19 to the Receptor CD9. American Journal of Reproductive Immunology, 59, 251-258.
[14] Martínez, F.F., Knubel, C.P., Sánchez, M.C., Cervi, L. and Motrán, C.C. (2012) Pregnancy-Specific Glycoprotein 1a Activates Dendritic Cells to Provide Signals for Th17-, Th2-, and Treg-Cell Polarization. European Journal of Immunology, 42, 1573-1584.
[15] Fialova, L., Kohoutova, B., Pelísková, Z., Malbohan, I. and Mikulíková, L. (1991) Serum Levels of Trophoblast-Specific Beta-1-Globulin (SP1) and Alpha-1-Fetoprotein (AFP) in Pregnant Women with Rheumatoid Arthritis. Ceská Gynekologie, 56, 166-170.
[16] Ha, C.T., Wu, J.A., Irmak, S., Lisboa, F.A. and Dizon, A.M.L. (2010) Human Pregnancy Specific Beta-1-Glycoprotein 1 (PSG1) Has a Potential Role in Placental Vascular Morphogenesis. Biology of Reproduction, 83, 27-35.
[17] Jurisicova, A., Antenos, M., Kapasi, K., Meriano, J. and Casper, R.F. (1999) Variability in the Expression of Trophectodermal Markers Beta-Human Chorionic Gonadotrophin, Human Leukocyte Antigen-G and Pregnancy Specific Beta-1 Glycoprotein by the Human Blastocyst. Human Reproduction, 14, 1852-1858.
[18] Bersinger, N.A. and Odegard, R.A. (2004) Second and Third-Trimester Serum Levels of Placental Proteins in Preeclampsia and Small-for-Gestational Age Pregnancies. Acta Obstetrics and Gynecology of Scandavania, 83, 37-45.
[19] Pihl, K., Larsen, T., Laursen, I., Krebs, L. and Christiansen, M. (2009) First Trimester Maternal Serum Pregnancy- Specific Beta-1-Glycoprotein (SP1) as a Marker of Adverse Pregnancy Outcome. Prenatal Diagnosis, 29, 1256-1261.
[20] Chesley, L.C. (1985) Diagnosis of Preeclampsia. Obstetrics and Gynecology, 65, 423-425.
[21] Teran, E., Escudero, C., Moya, W., Flores, M., Vallance, P. and Lopez-Jaramillo, P. (2001) Elevated C-Reactive Protein and Pro-Inflammatory Cytokines in Andean Women with Preeclampsia. International Journal of Obstetrics and Gynecology, 75, 243-249.
[22] Pathare, A., Al Kindi, S., Alnaqdy, A., Daar, S., Knox-Macauly, H. and Dennison, D. (2004) Cytokine Profile of Sickle Cell Disease in Oman. American Journal of Hematology, 77, 323-328.
[23] Onyemelukwe, G.C., Ekwempu, C.C. and Alexander, L.C. (1985) Pregnancy Specific Glycoprotein (PSG1) in Normal Pregnancy in Nigeria. Internal Journal of Obstetrics and Gynaecology, 23, 347-349.
[24] Silver, R.M., Heyborne, K.D. and Leslie, K.K. (1993) Pregnancy Specific Beta 1 Glycoprotein (SP-1) in Maternal Serum and Ammiotic Fluid; Pre-Eclampsia, Small for Gestational Age Fetus and Fetal Distress. Placenta, 14, 583-589.
[25] Horne, C.H., Towler, C.M., Pugh-Humphreys, R.G., Thomson, A.W. and Bohn, H. (1976) Pregnancy Specific Beta-1- Glycoprotein: A Product of the Syncytiotrophoblast. Experientia, 32, 1197-1199.
[26] Lin, T.M., Halbert, S.P. and Kiefer, D. (1976) Quantitative Analysis of Pregnancy-Associated Plasma Proteins in Human Placenta. Journal of Clinical Investigations, 57, 466-472.
[27] Lisboa, F.A., Warren, J., Sulkowski, G., Aparicio, M., David, G., et al. (2011) Pregnancy-Specific Glycoprotein 1 Induces Endothelial Tubulogenesis through Interaction with Cell Surface Proteoglycans. Journal of Biological Chemistry, 286, 7577-7586.
[28] Sacks, G., Sargent, I. and Redman, C. (1999) An Innate View of Human Pregnancy. Immunology Today, 20, 114-118.
[29] Snyder, S.K., Wessner, D.H. Wessells, J.L., Waterhouse, R.M., Zimmermann, W. and Dveksler, G.S. (2001) Pregnancy-Specific-Beta1 Glycoprotein Function as Immunomodulators by Inducing Secretion of IL-10, IL6 and TGF by Human Monocytes. American Journal of Immunology, 45, 205-216.
[30] Blois, S.M., Sulkowski, M., Tirado-Gonzalez, I., Warren, J., Freitag, N., Klabb, B.F., Rifkin, D., Fuss, I., Strober, W. and Dveksler, G.S. (2014) Pregnancy Specific Beta-1 Activates Transformation Growth Factor Beta-1 and Prevent Dextran Sodium Sulfate-Induced Colitis in Mice. Mucosal Immunology, 7, 348-358.
[31] Masson, G.M., Anthony, F. and Wilson, M. (1983) Value of Schwangerschftsprotein 1 (SP1) and Pregnancy-Associated Plasma Protein A (PAPP-A) in the Clinical Management of Threatened Abortion. British Journal of Obstetrics and Gynaecology, 90, 146-149.
[32] Tamsen, L., Johansson, S.G. and Axelsson, O. (1983) Pregnancy-Specific Beta 1-Glycoprotein (SP1) in Serum from Women with Pregnancies Complicated by Intrauterine Growth Retardation. Journal of Perinatal Medicine, 11, 19-25.
[33] Arnold, L.L., Doherty, T.M., Flor, A.W., Simon, J.A., Chou, J.Y., Chan, W.Y. and Mansfield, B.C. (1999) Pregnancy- Specific Glycoprotein Gene Expression in Recurrent Aborters: A Potential Correlation to Interleukin-10 Expression. American Journal of Reproductive Immunology, 41, 174-182.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.